Pharmaceuticals & Therapeutics

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

Milliken's Borchers brand targets Asia's booming coatings market with tailored, eco-friendly additives and expanded technical support from its Pune hub.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

A landmark deal will deploy advanced Belgian particle accelerators across India, aiming to revolutionize cancer diagnostics and patient access in a booming market.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

The Nashville-based clinic brings its luxury, results-driven skincare model to Arlington, VA, tapping into national wellness trends and rapid growth.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

A new partnership brings prescription pain patches directly to consumers online, signaling a major shift in how patients access affordable generic medicines.

AVEO Oncology's ficlatuzumab advances in a pivotal Phase 3 trial, offering new hope for patients with a difficult-to-treat form of head and neck cancer.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

Amid market volatility, the S&P 500 firm reinforces its financial strength with a massive share repurchase program and its 34th year of dividend growth.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

United Vein & Vascular Centers opens its sixth Phoenix-area clinic in Mesa, bringing minimally invasive treatments to a region with growing healthcare needs.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

Utah's fast-growing wellness brand launches 15 bestsellers nationwide, signaling a major shift toward ingredient transparency in mass-market retail.